Results 191 to 200 of about 144,849 (341)

Disease activity classification based on routinely collected blood tests in a prospective paediatric inflammatory bowel disease inception cohort

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract We have shown that disease‐activity clusters derived from routine blood tests in administrative data predicted disease outcomes in Crohn's disease (CD). We aimed to validate these findings on a prospective inception cohort. Hierarchical clustering grouped children newly diagnosed with CD by similarities in diagnostic blood tests and fecal ...
Rona Lujan, Oren Ledder, Dotan Yogev, Raffi Lev‐Tzion, Esther Orlanski‐Meyer, Shira Yuval Bar‐Asher, Ibrahim Shamasnah, Eyal Shteyer, Leora Gotesdyner, Mohammad Shawar, Elena Feldman, Gabriella Aschkenasy, Anna Lev, Dan Turner   +13 more
wiley   +1 more source

Su1004 Using Search Engine Query Data to Explore Epidemiology of Common Gastrointestinal Symptoms [PDF]

, 2016
Awad, Mohannad, Breyer, Benjamin, Day, Lukejohn, Hassid, Benjamin, Sewell, Justin L   +4 more
core   +2 more sources

Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients

, 2012
Mariam Aguas
openalex   +2 more sources

Vedolizumab for extraintestinal manifestations in pediatric inflammatory bowel disease: Results from the VedoKids study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Extraintestinal manifestations (EIMs) manifest in 6%‐47% of patients with inflammatory bowel disease (IBD). Here, we characterize the course of EIMs in pediatric patients receiving vedolizumab included in the VedoKids cohort study. This was a subgroup analysis of the pediatric VedoKids cohort, a multicenter, prospective study of children (aged
Giulia D'Arcangelo, Dan Turner, Oren Ledder, Esther Orlanski‐Meyer, Efrat Broide, Maya Granot, Manar Matar, Seamus Hussey, Anat Yerushalmy‐Feler, Christoph Norden, Erasmo Miele, Marina Aloi   +11 more
wiley   +1 more source

Gastric and Duodenal Mucosal Healing With Risankizumab in Upper Gastrointestinal Crohn's Disease. [PDF]

ACG Case Rep J
Chatto M, Sedano R, Jairath V.
europepmc   +1 more source

Crohn's Disease [PDF]

Postgraduate Medical Journal, 1953
openaire   +2 more sources

Anti‐tumor necrosis factor‐α monotherapy versus combo therapy with immunosuppressant in pediatric inflammatory bowel disease: A real‐life study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives The aim of the study is to evaluate the efficacy of anti‐tumor necrosis factor (TNF)‐α monotherapy versus combination anti‐TNF‐α and immunosuppressive therapy. Methods A single‐center, retrospective, observational study was conducted on inflammatory bowel disease (IBD) children.
Flora Fedele, Massimo Martinelli, Caterina Strisciuglio, Elena Scarpato, Annamaria Staiano, Erasmo Miele   +5 more
wiley   +1 more source

Novel association of metastatic Crohn's disease and Wolman disease

JAAD Case Reports, 2022
Amal AlAsmari, MD, Reema AlEssa, MD, Waleed AlAjroush, MD, FRCPC, FAAD, Rayan AlKhodair, MD, FRCPC, FAAD, Sukainah AlHaddad, MD   +4 more
doaj   +1 more source

Therapy de‐escalation in pediatric patients with inflammatory bowel disease in remission: Data analysis from the CEDATA registry

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives There are no standardized criteria about stepping down from combination therapy (immunomodulator and tumor necrosis factor (TNF)‐alpha‐inhibitors) in children with inflammatory bowel disease (IBD) to reduce risk for side effects. Our aim was to describe how de‐escalation has been performed in a large pediatric cohort and to find ...
Sila Cekin, Christoph Huenseler, Serdar Cantez, Ilse Broekaert, Jan de Laffolie, CEDATA‐GPGE® Study Group   +5 more
wiley   +1 more source

Using machine learning to predict clinical remission with exclusive enteral nutrition in pediatric Crohn disease

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Exclusive enteral nutrition (EEN) is a first‐line treatment for induction of remission in luminal pediatric Crohn disease (pCD). However, as the efficacy of EEN varies from patient to patient, there is a need to distinguish between responders and nonresponding patients. This study had two aims.
Ricardo G. Suarez Suarez, Daniel G. McClement, Roberto Vega, Hien Q. Huynh, Ayub Shaikh, Anthony Otley, Kevan Jacobson, Mary Sherlock, David R. Mack, Colette Deslandres, Wael El‐Matary, Eileen Crowley, Jennifer deBruyn, Thomas Walters, Anne M. Griffiths, Russell Greiner, Eytan Wine, The Canadian Children IBD Network, Jeff Critch, Lara Hart, Rilla Schneider, Kevin Bax, Eric I. Benchimol   +22 more
wiley   +1 more source